Induction of ferroxidase enzymatic activity by copper reduces MPP+-evoked neurotoxicity in rats

Neuroscience Research

Volumn 75, Issue 3, 2013, Pages 250-255

  Rubio Osornio, Moisés ^a   Montes, Sergio ^a   Heras Romero, Yessica ^a   Guevara, Jorge ^b   Rubio, Carmen ^a   Aguilera, Penélope ^a   Rivera Mancia, Susana ^a   Floriano Sánchez, Esaú ^c   Monroy Noyola, Antonio ^a,d   Ríos, Camilo ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Aérea Escuela Militar de Graduados de Sanidad and Instituto Politécnico   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

Author keywords

Ceruloplasmin; Copper; Ferroxidase activity; MPP+; Parkinson's disease

Indexed keywords

CERULOPLASMIN; COPPER; FERROUS ION; IRON;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; ENZYME ACTIVITY; LIPID PEROXIDATION; MESENCEPHALON; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CERULOPLASMIN; COPPER; COPPER SULFATE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; MALE; MESENCEPHALON; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 84875963559     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2012.12.003     Document Type: Article

References (31)

1. + neurotoxicity in mice. Neurochem. Res. 2001, 26:59-64.
2. +, induces damage of striatal cell nuclei in Sprague-Dawley rats. J. Chem. Neuroanat. 2006, 32:90-100.
3. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Pakinson's disease. Biochem. Pharmacol. 2002, 64:1037-1048.
4. Bharatkumar N.P., Robert D.J., Suh Y.J., Qinzhang Z., Julien J.P., Samuel D. Ceruloplasmin regulates iron levels in the in the CNS and prevents free radical injury. J. Neurosci. 2002, 22(15):6578-6586.
5. Blum D., Torch S., Lambeng N., Nissou M., Benabid A., Sadoul R., Verna M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
6. Boll M., Sotelo J., Otero E., Alcaraz-Zubeldia M., Ríos C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci. Lett. 1999, 265(3):155-158.
7. Chen H., Attieh Z.K., Su T., Syed B.A., Gao H., Alaeddine R.M., Fox T.C., Usta J., Naylor C.E., Evans R.W., McKie A.T., Anderson G.J., Vulpe C.D. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 2004, 103(10):3933-3939.
8. Crow A., Morgan E.H. Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals. J. Nutr. 1996, 126:183-194.
9. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J. Neurochem. 1994, 63:1609-1623.
10. Harris Z.L., Klomp W.J., Gitlin J. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr. 1998, 67:972-977.
11. Hochstrasser H., Tomiuk J., Walter U., Behnke S., Spiegel J., Krüger R., Becker G., Riess O., Berg D. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J. 2005, 19:1851-1853.
12. Livak K., Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta (CT)) Method. Methods 2001, 25(4):402-408.
13. Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
14. Lyubimov A., Smith J., Rousselle S., Mercieca M., Tomaszewski J., Smith A., Levine B. The effects of tetrathiomolybdate (TTM, NSC-714598) and copper supplementation on fertility and early embryonic development in rats. Reprod. Toxicol. 2004, 19:223-233.
15. Matusch A., Depboylu C., Palm C., Wu B., Höglinger G.U., Schäfer M.K., Becker J.S. Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). J. Am. Soc. Mass. Spectrom. 2010, 21:161-171.
16. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 1994, 168:251-253.
17. Nilsson U.A., Bassen M., Sävman K., Kjellmer I. A simple and rapid method for the determination of free iron in biological fluids. Free Radic. Res. 2002, 36(6):677-684.
18. Pérez-Severiano F., Santamaría A., Pedraza-Chaverri J., Medina-Campos O.M., Rios C., Segovia J. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem. Res. 2004, 29:729-733.
19. Prohaska J., Gybina A. Intracellular copper transport in mammals. J. Nutr. 2004, 134:1003-1006.
20. Ríos C., Alvarez-Vega R., Rojas P. Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacol. Toxicol. 1995, 76:348-352.
21. Rivera-Mancia Y., Pérez-Neri I., Ríos C., Tristán-López L., Rivera-Espinosa L., Montes S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact. 2010, 186(2):184-199.
22. + in rats. Neurochem. Int. 2009, 54(7):447-451.
23. Santamaría A., Ordaz-Moreno J., Rubio-Osornio M., Solís-Hernández F., Ríos C. Neuroprotective effect of dapsone against quinolinate- and kainate-induced striatal neurotoxicities in rats. Pharmacol. Toxicol. 1997, 81(6):271-275.
24. Scheiber I.F., Dringer R. Astrocytes functions in the copper homeostasis in the brain. Neurochem. Int. 2012, Doi.org/10.1016/j.neuint.2012.08.017.
25. Schielf M., Gitlin J. Copper homeostasis in the CNS. Mol. Neurobiol. 2006, 33:81-90.
26. + or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol. Biochem. Behav. 2006, 84:376-392.
27. Sziraki I., Mohanakumar K.P., Rauhala P., Kim H.G., Yeh K.J., Chiueh C.C. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 1998, 85:1101-1111.
28. Toulouse A., Sullivan A. Progress in Parkinson's disease -where do we stand?. Prog. Neurobiol. 2008, 85(4):376-392.
29. Vassiliev V., Harris Z., Zatta P. Ceruloplasmin in neurodegenerative disease. Brain Res. Rev. 2005, 49:633-640.
30. Videt-Gibou D., Belliard S., Bardou-Jacquet E., Troadec M.B., Le Lan C., Jouanolle A., Loréal O., Rivalan J., Brissot P. Iron excess treatable by copper supplementation in acquired aceruloplasminemia: a new form secondary human iron overload?. Blood 2009, 114(11):2360-2361.
31. Walter U., Niehaus L., Probst T., Benecke R., Meyer B., Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003, 60:74-77.